ERBB2 and colorectal carcinoma: BRAFV600E, KRASG12C mutation, ERBB2 (HER2) amplification, and various receptor tyrosine kinase (RTK) fusions are rare but potentially therapeutically relevant in colorectal cancer (CRC) (1, 2).